Zobrazeno 1 - 10
of 80
pro vyhledávání: ''
Autor:
Jonathan R. Stretch, Serigne Lo, Natalie S Osborne, Johanna M Dalton, Robyn P. M. Saw, Andrew J. Spillane, John F. Thompson, Gabrielle Williams
Publikováno v:
Melanoma Research. 31:232-241
Melanoma in-transit metastases (ITMs) can sometimes be difficult to manage by surgical excision due to their number, size or location. Treatment by intralesional injection of PV-10, a 10% solution of rose bengal, has been reported to be a simple, saf
Autor:
Mathilde Jalving, Geke A. P. Hospers, Jacco J de Haan, Ranko Gacesa, Rinse K. Weersma, Thijs T Wind, Arnau Vich Vila
Publikováno v:
Melanoma Research, 30(3), 235-246. LIPPINCOTT WILLIAMS & WILKINS
In patients with metastatic cancer, gut microbiome composition differs between responder and non-responders to immune checkpoint inhibitors. However, there is little consensus on the microbiome taxa associated with response or lack of response. Addit
Autor:
Piotr Rutkowski, Paweł Rogala, Magdalena Wiśniewska, Anna M. Czarnecka, Adrianna Gęga-Czarnota, Bożena Cybulska-Stopa, Łukasz Galus, Tomasz Kubiatowski, Paweł Teterycz, Marcin Rajczykowski, Jacek Mackiewicz, Marek Ziobro, Robert Dziura, Rafał Suwiński
Publikováno v:
Melanoma Research. 30:465-471
Despite considerable progress made in the treatment of patients with advanced melanoma, the majority of the patients treated with BRAF and mitogen-activated protein inhibitors (BRAFi and MEKi) experience a disease progression due to acquired resistan
Autor:
Benjamin Thomas, Tuan Anh Duong, Gurdeep Parmar, Daniel Brungs, Morteza Aghmesheh, Lucy Haggstrom
Publikováno v:
Melanoma Research. 29:533-538
Disseminated intravascular coagulation is a complex and potentially lethal complication of malignancy, in which the fundamental abnormality is excessive activation of the coagulation system. It is a rare complication of melanoma which can be difficul
Publikováno v:
Melanoma Research. 29:501-509
In several cancers, tumor progression is associated with the infiltration of tumor-associated macrophages (TAMs). The aim was to evaluate the prognostic significance of expression of CD163 and CD68 (TAMs' markers) and their correlation with vascular
Autor:
Colin R Lindsay, Pier Francesco Ferrucci, Giuseppe Tonini, Dara Stein, Victoria Atkinson, Paola Queirolo, Barbara Merelli, Philippe Legenne, Massimo Aglietta, Klaus Freivogel, Soizick Mesnage, Michele Del Vecchio, Helen Linardou, Bart Neyns, Salvador Martín-Algarra, Lindi Dalland, Vanna Chiarion-Sileni, Michael Millward, Jonathan Cebon, Rebecca A. Hinshelwood, Mike Lau
Publikováno v:
Melanoma Research. 29:527-532
Given the approval of dabrafenib in patients with BRAF-mutant metastatic melanoma, a better understanding of treatment patterns and clinical outcomes with dabrafenib in a clinical setting is warranted. We performed a retrospective chart review of pat
Autor:
Anders Albäck, Tanja Skyttä, Laura Kohtamäki, Micaela Hernberg, Pirkka Vikatmaa, Kalle Mattila, Siru Mäkelä, Susanna Juteau, Kristiina Tyynelä-Korhonen, Sanni K. A. Tulokas, Jussi Koivunen
Publikováno v:
Melanoma research. 31(5)
Isolated limb perfusion (ILP) is widely accepted as treatment for recurrent melanoma limited to the limbs. The use of ILP has decreased in recent years with the introduction of potentially effective new systemic therapies. We evaluated retrospectivel
Autor:
Jarrett J. Failing, Anagha Bangalore Kumar, Robert R. McWilliams, Svetomir N. Markovic, Roxana S. Dronca, Matthew S. Block, Ying Li, Jonas Paludo, Lisa A. Kottschade, Yiyi Yan, Jesus Vera Aguilera, Henan Zhang, Haidong Dong
Publikováno v:
Melanoma Research
Supplemental Digital Content is available in the text.
Management of PD-1 blockade resistance in metastatic melanoma (MM) remains challenging. Immunotherapy or chemotherapy alone provides limited benefit in this setting. Chemo-immunotherapy (CIT
Management of PD-1 blockade resistance in metastatic melanoma (MM) remains challenging. Immunotherapy or chemotherapy alone provides limited benefit in this setting. Chemo-immunotherapy (CIT
Autor:
Christian U. Blank, Johannes V. Van Thienen, Dieta Brandsma, John B. A. G. Haanen, Willem Boogerd, Marnix H Geukes Foppen
Publikováno v:
Melanoma Research. 28:126-133
Patients with brain metastases (BM) from melanoma have an overall survival (OS) of 2-6 months after whole-brain radiotherapy. Targeted therapy (TT) is an effective treatment for BRAF-mutated metastatic melanoma. Moreover, recent studies indicate intr
Autor:
Philippe Bertheau, Cécile Pagès, Céleste Lebbé, Nelson Lourenco, Nadim Mourad, Julie Delyon, Matthieu Allez, Clara Allayous, A. Ballon, Barouyr Baroudjian, Pirayeh Eftekhari
Publikováno v:
Melanoma research. 29(5)
Gastrointestinal toxicities of MEK inhibitors in melanoma patients are frequent. In clinical trials, the most common digestive adverse events were nausea, vomiting, and diarrhoea. However, severe toxicities such as colitis and gastrointestinal perfor